drugset / Trial / NCT02224690

A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults

NCT02224690

Phase 3 Completed 171 enrolled Jazz Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the efficacy of GWP42003-P as adjunctive treatment in reducing the number of drop seizures when compared with placebo, in participants with Lennox-Gastaut Syndrome (LGS).

Timeline

Start
2015-04-28
Primary completion
2016-03-18
Completion
2016-03-18

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cannabidiol Other / unclassified 20 mg/kg Oral